AI assistant
Anteris Technologies Global Corp. — Board/Management Information 2018
Apr 30, 2018
33869_rns_2018-04-30_4bed6235-8918-4fbd-a5e1-f2b2ccc462aa.pdf
Board/Management Information
Open in viewerOpens in your device viewer
01.05.18
==> picture [452 x 24] intentionally omitted <==
ASX ANNOUNCEMENT
ASX Market Announcements Australian Securities Exchange Limited 10[th] Floor, 20 Bond Street SYDNEY NSW 2000
Admedus Limited (ASX:AHZ)
FUTURE IN FOCUS AS NEW VP, DEVELOPMENT APPOINTED
Admedus Limited (ASX:AHZ) is pleased to announce the appointment of Mr Michael Oswell to the newly created role of Vice President, Development. Based in the US, Michael will be responsible for accelerating the product pipeline, including our portfolio of 3D surgical solutions and the TAVR project.
Michael brings extensive experience in the medical technology industry, including senior leadership roles with Guidant Corp. (Boston Scientific) and Medtronic Pty Ltd.
In his most recent role, Senior Program Manager Medtronic ( Cardiac Rhythm & Heart Failure Operations PMO) , Michael was required to develop, coordinate, and drive initiatives which included activities such as, portfolio management, project selection / vetting, tracking and reporting, and setting project management standards across the organisation.
CEO Wayne Paterson welcomed Michael’s appointment,
“Michael has a strong track record as a results-driven leader in the medtech environment. He will be an excellent addition to the Admedus leadership team and his technical skill and experience will be an enormous advantage as we look to progress our range of new products in our development pipeline.”
“His background in product development for some of the leading companies in the medtech industry will bring invaluable new perspective to our portfolio of development projects.”
He holds a Bachelor of Science from the University of Wisconsin, as well as, an Associates of Applied Science Degree and a Pre-Bachelor of Mechanical Engineering.
He will commence as Admedus VP, Development in Minneapolis on 15 May 2018.
ENDS
Admedus Limited ABN 35 088 221 078
Customer Service T 1300 550 310 F 1300 880 398 International T: +61 8 9266 0100 F: +61 8 9266 0199
E: [email protected] W: www.admedus.com Brisbane • Minneapolis Zurich • Singapore
Registered Office Level 9 301 Coronation Drive Milton QLD 4064
==> picture [452 x 24] intentionally omitted <==
About Admedus Limited
Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.
Website: www.admedus.com Facebook: www.facebook.com/Admedus Twitter: @Admedus
For more information, please contact:
Admedus Limited Barbara Ferres +61 7 3152 3216 [email protected]
Admedus Limited ABN 35 088 221 078
Customer Service T 1300 550 310 F 1300 880 398 International T: +61 8 9266 0100 F: +61 8 9266 0199
E: [email protected] W: www.admedus.com Brisbane • Minneapolis Zurich • Singapore
Registered Office Level 9 301 Coronation Drive Milton QLD 4064